SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    H. Zhao, L. Wang, R. Wei, D. Xiu, M. Tao, J. Ke, Y. Liu, J. Yang, T. Hong, Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway, Diabetes, Obesity and Metabolism, 2014, 16, 9
  2. 2
    J. G. Coen van Hasselt, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema, Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error, Investigational New Drugs, 2014,

    CrossRef

  3. 3
    Jeppe Skov, Effects of GLP-1 in the Kidney, Reviews in Endocrine and Metabolic Disorders, 2014, 15, 3, 197

    CrossRef

  4. 4
    P. Arnouts, D. Bolignano, I. Nistor, H. Bilo, L. Gnudi, J. Heaf, W. v. Biesen, Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties, Nephrology Dialysis Transplantation, 2014, 29, 7, 1284

    CrossRef

  5. 5
    Mark E. Williams, Rajesh Garg, Glycemic Management in ESRD and Earlier Stages of CKD, American Journal of Kidney Diseases, 2014, 63, 2, S22

    CrossRef

  6. 6
    Wenjun Ji, Xinlin Chen, Juan Lv, Meng Wang, Shuting Ren, Bingxiang Yuan, Bing Wang, Lina Chen, Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice, International Journal of Endocrinology, 2014, 2014, 1

    CrossRef

  7. 7
    Mette Bohl, Ann Overgaard, Anna Pietraszek, Kjeld Hermansen, Management of Type 2 diabetes with liraglutide, Diabetes Management, 2014, 4, 2, 189

    CrossRef

  8. 8
    Jean-Daniel Lalau, Paul Arnouts, Adnan Sharif, Marc E De Broe, Metformin and other antidiabetic agents in renal failure patients, Kidney International, 2014,

    CrossRef

  9. 9
    Anne Esselink, Nynke Scherpbier-de Haan, Kees Kramers, Nierinsufficiëntie en medicatie, Bijblijven, 2014, 30, 3, 54

    CrossRef

  10. 10
    Hisazumi Araki, Yuki Tanaka, Syohei Yoshida, Yoshikata Morita, Shinji Kume, Keiji Isshiki, Shin-ichi Araki, Takashi Uzu, Atsunori Kashiwagi, Hiroshi Maegawa, Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment, Journal of Diabetes Investigation, 2014, 5, 4
  11. 11
    Carlo B. Giorda, Elisa Nada, Barbara Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature, Endocrine, 2014, 46, 3, 406

    CrossRef

  12. 12
    Karoline von Websky, Christoph Reichetzeder, Berthold Hocher, Physiology and pathophysiology of incretins in the kidney, Current Opinion in Nephrology and Hypertension, 2014, 23, 1, 54

    CrossRef

  13. 13
    Yoshiaki Tamura, Yoshiyuki Kimbara, Shingo Funatsuki, Suguru Mabuchi, Remi Kodera, Ayako Yoshimoto, Yuko Chiba, Seijiro Mori, Hideki Ito, Atsushi Araki, A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide, Diabetology International, 2013, 4, 1, 71

    CrossRef

  14. 14
    Angelo Avogaro, Guntram Schernthaner, Achieving glycemic control in patients with type 2 diabetes and renal impairment, Acta Diabetologica, 2013, 50, 3, 283

    CrossRef

  15. 15
    Ryuji Matsushita, Shotaro Taniguchi, Keiichi Matsuzaki, Yoshiyuki Furumatsu, Yumiko Yanagihara, Kazuko Harada, Koujin Nakayama, Kaori Kato, Tomonori Nakashima, Shuji Nakamura, Masanao Nagatomo, An examination of switching from insulin to glucagon-like peptide-1 analogue liraglutide in hemodialysis patients with type 2 diabetes: A descriptive epidemiology study, Nihon Toseki Igakkai Zasshi, 2013, 46, 9, 923

    CrossRef

  16. 16
    Robert R. Henry, Antihyperglycemic Drug Therapy in Patients with Diabetes and CKD: A Closer Look at Incretin-Based Therapies, Endocrine Practice, 2013, 19, s1, 19

    CrossRef

  17. 17
    James R. LaSalle, Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes, Osteopathic Family Physician, 2013, 5, 1, 51

    CrossRef

  18. 18
    Maria J Jespersen, Filip K Knop, Mikkel Christensen, GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 1, 17

    CrossRef

  19. 19
    Anne Plum, Lisbeth Bjerring Jensen, Jesper Bøggild Kristensen, In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis, Journal of Pharmaceutical Sciences, 2013, 102, 8
  20. 20
    Kyle R. Peters, Liraglutide for the Treatment of Type 2 Diabetes, American Journal of Therapeutics, 2013, 20, 2, 178

    CrossRef

  21. 21
    Ashley Therasse, Amisha Wallia, Mark E. Molitch, Management of Post-Transplant Diabetes, Current Diabetes Reports, 2013, 13, 1, 121

    CrossRef

  22. 22
    Colleen Flynn, George L. Bakris, Noninsulin glucose-lowering agents for the treatment of patients on dialysis, Nature Reviews Nephrology, 2013, 9, 3, 147

    CrossRef

  23. 23
    André J Scheen, Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 5, 529

    CrossRef

  24. 24
    KY Thong, C Walton, REJ Ryder, Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit, Practical Diabetes, 2013, 30, 2
  25. 25
    Manfredi Rizzo, Dragana Nikolic, Maciej Banach, Rosaria Vincenza Giglio, Angelo Maria Patti, Vittoria Di Bartolo, Annamaria Tamburello, Antonella Zabbara, Giuseppina Pecoraro, Giuseppe Montalto, Ali A Rizvi, The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective, Clinical Lipidology, 2013, 8, 2, 173

    CrossRef

  26. 26
    Yuichi Terawaki, Takashi Nomiyama, Yuko Akehi, Hiromasa Takenoshita, Ryoko Nagaishi, Yoko Tsutsumi, Kunitaka Murase, Hisahiro Nagasako, Nobuya Hamanoue, Kaoru Sugimoto, Ayako Takada, Kenji Ito, Yasuhiro Abe, Yoshie Sasatomi, Satoru Ogahara, Hitoshi Nakashima, Takao Saito, Toshihiko Yanase, The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis, Diabetology & Metabolic Syndrome, 2013, 5, 1, 10

    CrossRef

  27. 27
    Nihon Toseki Igakkai Zasshi, 2013, 46, 3, 344

    CrossRef

  28. 28
    Bruce Bode, An overview of the pharmacokinetics, efficacy and safety of liraglutide, Diabetes Research and Clinical Practice, 2012, 97, 1, 27

    CrossRef

  29. 29
    Dominique Xavier Brown, Marc Evans, Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective, Journal of Nutrition and Metabolism, 2012, 2012, 1

    CrossRef

  30. 30
    L. Blonde, E. Montanya, Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents, Diabetes, Obesity and Metabolism, 2012, 14,
  31. 31
    Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber, Carol H. Wysham, Current Issues in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes, Endocrine Practice, 2012, 18, s3, 6

    CrossRef

  32. 32
    Amir Hanna, Vincent Woo, Jean-François Yale, Elaine M. Cooke, Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes, Canadian Journal of Diabetes, 2012, 36, 1, 9

    CrossRef

  33. 33
    KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update, American Journal of Kidney Diseases, 2012, 60, 5, 850

    CrossRef

  34. 34
    S Koppa Narayana, SK Talab, MA Elrishi, Liraglutide-induced acute kidney injury, Practical Diabetes, 2012, 29, 9
  35. 35
    Yaman Kaakeh, Sanna Kanjee, Kevin Boone, James Sutton, Liraglutide-Induced Acute Kidney Injury, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012, 32, 1
  36. 36
    Hirosuke Nakata, Seita Sugitani, Shuhei Yamaji, Satoko Otsu, Yoshihito Higashi, Yumiko Ohtomo, Gen Inoue, Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease, Internal Medicine, 2012, 51, 21, 3045

    CrossRef

  37. 37
    R.C.L. Page, A worldwide yearly survey of new data in adverse drug reactions and interactions, 2012,

    CrossRef

  38. 38
    C. Hasslacher, Antidiabetische Therapie bei Niereninsuffizienz, Der Nephrologe, 2011, 6, 5, 400

    CrossRef

  39. 39
    Bruce W. Bode, Jason Brett, Ali Falahati, Richard E. Pratley, Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies, The American Journal of Geriatric Pharmacotherapy, 2011, 9, 6, 423

    CrossRef

  40. 40
    S. Halimi, Contrôler la glycémie chez les diabétiques atteints de maladie rénale jusqu’au stade de la dialyse, Médecine des Maladies Métaboliques, 2011, 5, S19

    CrossRef

  41. 41
    Vivian A. Fonseca, Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca, The American Journal of Medicine, 2011, 124, 1, S54

    CrossRef

  42. 42
    Caroline M. Perry, Liraglutide, Drugs, 2011, 71, 17, 2347

    CrossRef

  43. 43
    M. J. Davies, R. Kela, K. Khunti, Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes, Diabetes, Obesity and Metabolism, 2011, 13, 3
  44. 44
    Kohei Kaku, Liraglutide for the treatment of diabetes mellitus in Japan, Diabetes Management, 2011, 1, 4, 451

    CrossRef

  45. 45
    Evan M. Sisson, Liraglutide: Clinical Pharmacology and Considerations for Therapy, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 9
  46. 46
    Gina J. Ryan, Yolanda Hardy, Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes, Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 3
  47. 47
    Jaime A. Davidson, Jason Brett, Ali Falahati, David Scott, Mild Renal Impairment and the Efficacy and Safety of Liraglutide, Endocrine Practice, 2011, 17, 3, 345

    CrossRef

  48. 48
    Jaime A. Davidson, Jason Brett, Ali Falahati, David Scott, Mild Renal Impairment and the Efficacy and Safety of Liraglutide, Endocrine Practice, 2011, 17, 3, 345

    CrossRef

  49. 49
    B. Charbonnel, B. Cariou, Pharmacological management of type 2 diabetes: the potential of incretin-based therapies, Diabetes, Obesity and Metabolism, 2011, 13, 2
  50. 50
    Gina J. Ryan, Karla T. Foster, Lynetta Johnson Jobe, Review of the Therapeutic Uses of Liraglutide, Clinical Therapeutics, 2011, 33, 7, 793

    CrossRef

  51. 51
    Liza K. Phillips, Johannes B. Prins, Update on incretin hormones, Annals of the New York Academy of Sciences, 2011, 1243, 1
  52. 52
    R.C.L. Page, A worldwide yearly survey of new data in adverse drug reactions, 2011,

    CrossRef

  53. 53
    Dennis J. Cada, Terri L. Levien, Danial E. Baker, Formulary Drug Reviews - Liraglutide, Hospital Pharmacy, 2010, 45, 7, 552

    CrossRef

  54. 54
    Nicole R. Pinelli, Carol L. Moore, Sarah Tomasello, Incretin-based Therapy in Chronic Kidney Disease, Advances in Chronic Kidney Disease, 2010, 17, 5, 439

    CrossRef

  55. 55
    Anne Flint, Khalil Nazzal, Pawel Jagielski, Charlotte Hindsberger, Milan Zdravkovic, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide, British Journal of Clinical Pharmacology, 2010, 70, 6
  56. 56
    Nasser E. Mikhail, Is Liraglutide a Useful Addition to Diabetes Therapy?, Endocrine Practice, 2010, 16, 6, 1028

    CrossRef

  57. 57
    F.J. Ampudia-Blasco, C. Calvo Gómez, X. Cos Claramunt, J. García Alegría, E. Jódar Gimeno, J.J. Mediavilla Bravo, P. Mezquita Raya, J. Navarro Pérez, M. Puig Domingo, Liraglutida en el tratamiento de la diabetes tipo 2:, Avances en Diabetología, 2010, 26, 4, 226

    CrossRef

  58. 58
    Francisco Javier Ampudia-Blasco, Carlos Calvo Gómez, Xavier Cos Claramunt, Javier García Alegría, Esteban Jódar Gimeno, José Javier Mediavilla Bravo, Pedro Mezquita Raya, Jorge Navarro Pérez, Manel Puig Domingo, Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use, Expert Review of Endocrinology & Metabolism, 2010, 5, 6, 799

    CrossRef

  59. 59
    Marta Letizia Hribal, Giorgio Sesti, Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes, Expert Review of Endocrinology & Metabolism, 2010, 5, 4, 495

    CrossRef

  60. 60
    Amanda Y. Wang, Meg Jardine, Vlado Perkovic, Kidney Disease in Diabetes,